Climb Bio (CLYM) Net Cash Flow (2020 - 2026)

Climb Bio (CLYM) has 7 years of Net Cash Flow data on file, last reported at -$27.3 million in Q1 2026.

• Quarterly Net Cash Flow rose 53.03% year-over-year to -$27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.7 million (up 72.8% YoY) and the FY2025 annual result came in at -$51.5 million, down 769.94% from the prior year.
• Net Cash Flow declined to -$27.3 million in Q1 2026, from $9.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $118.1 million in Q2 2024 to a low of -$77.1 million in Q3 2024.
• A 5-year average of -$2.3 million and a median of $1.7 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow sank 654.12% — and 2024, when it soared 1337.58%.
• Tracing CLYM's Net Cash Flow over 5 years: stood at $5.8 million in 2022, then surged by 519.13% to $36.1 million in 2023, then tumbled by 263.18% to -$58.9 million in 2024, then soared by 116.78% to $9.9 million in 2025, then sank by 376.55% to -$27.3 million in 2026.
• The last three Net Cash Flow figures came in at -$27.3 million (Q1 2026), $9.9 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.